Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease
Study Details
Study Description
Brief Summary
A phase I trial to study the safety of mobilization of stem cells with G-CSF and Mozobil in patients with chronic liver disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Liver cirrhosis in humans represents the end stage of chronic liver injury. Supply of "new" stem cells to the liver could regenerate hepatocytes and restore the lost function. Delivery of Mesenchymal Stem Cells (MSCs) has been shown in animal models and limited clinical trials to result in improved liver disease (MELD) score.
In preclinical studies we have demonstrated that the combination of G-CSF plus Mozobil can effectively mobilize both hematopoietic stem cells (HSCs) and MSCs into the peripheral circulation. While G-CSF only mobilizes HSCs.
The clinical trial will test the safety of treating patients with end stage liver disease with G-CSF and Mozobil to mobilize MSCs into the peripheral circulation.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Mobilization with G-CSF plus Mozobil Patients will receive G-CSF (Filgrastim) plus Mozobil (Plerixafor) |
Drug: Mobilization with G-CSF and Mozobil
Treatment with drugs for mobilization of MSCs
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Toxicity as measured by bone pain, hematologic parameters, GI measures and renal parameters [12 months]
The primary end point for this study is the safety of mobilization of stem cells in patients with end stage liver disease. Adverse events will be documented to assess safety.
Secondary Outcome Measures
- Effects of Mobilization [12 months]
The secondary objective is to study the mobilization of stem cells, including MSCs, to the peripheral circulation and the effect on liver function. Functional assays will define the levels of heamtopoietic stem cells (CD34+ cells) and MSCs (CFU-F) in the circulation of patients.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with a clinical diagnosis of cirrhosis Age greater than or equal to 18 years MELD score less than or equal to 12 able to provide informed consent HIV and HBsAg seronegative Platelet count >50,000, WBC count > 2,000 No history of malignancy within the last 5 years, except for non-melanoma skin cancer or cervical carcinoma in situ No lesions suspicious for liver cancer on CT and/or MRI within prior 4 months
Exclusion Criteria:
Patients with acute or subacute onset of liver disease Patients who have received a liver transplant Age < 18 MELD score >12 Patients whose MELD scores are currently less than or equal to 12 but with history of prior deterioration with MELD score >12 Unable to provide informed consent Patients with HIV or HBsAg seropositivity Pregnant or lactating females Enrolled in another research protocol Any condition that precludes serial follow up Patients with history of malignancy within the last 5 years, except for non-melanoma skin cancer or cervical carcinoma in situ Any lesions suspicious for liver cancer on CT and/or MRI within prior 4 months Patients with palpable splenomegaly on physical examination ANy condition that in the investigators opinion would likely increase the risk of particpation or would likely confound interpretation of the data
-
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Medicine and Dentistry of New Jersey | Newark | New Jersey | United States | 07101 |
Sponsors and Collaborators
- Proteonomix, Inc.
- University of Medicine and Dentistry of New Jersey
- Numoda
Investigators
- Principal Investigator: Baburao Koneru, MD, University of Medicine and Dentistry of New Jersey
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Prot001